Table 1. Patient Characteristics in Each Group.
| Characteristic | Age Group, No. (%) | Fisher Test (P Value) | |
|---|---|---|---|
| ≤65 y (n = 54) |
>65 y (n = 38) |
||
| Demographic Characteristics of 92 Patients | |||
| Age, mean (SD), y | 48.1 (12.5) | 74.8 (6.9) | |
| Sex | .50 | ||
| Male | 30 (56) | 24 (63) | |
| Female | 24 (44) | 14 (34) | |
| Relevant Disease-Associated Characteristics | |||
| AJCC stage at treatment | .06 | ||
| IV M1a | 10 (18) | 5 (13) | |
| IV M1b | 7 (13) | 13 (34) | |
| IV M1c | 37 (69) | 20 (53) | |
| Genotype | .77 | ||
| BRAF | 20 (37) | 11 (29) | |
| NRAS | 13 (24) | 12 (32) | |
| Other (GNAQ, KIT) | 2 (4) | 2 (5) | |
| Wild type | 19 (35) | 13 (34) | |
| Duration between initial diagnosis and first systemic treatment, mo | .01 | ||
| <12 | 30 (83) | 23 (61) | |
| ≥12 | 24 (17) | 15 (39) | |
| BMI | .87 | ||
| Mean | 25.7 | 25.4 | |
| Median (q1, q3) [range] | 24.9 (22.0, 28.6) [17.6-35.5] | 25.5 (21.7, 28.4) [15-36.9] | |
| History of autoimmune disease | .68 | ||
| No | 51 (95) | 35 (92) | |
| Yes | 3 (5) | 3 (8) | |
| Comorbidity score CIRS | <.001 | ||
| Mean | 2.46 | 5.0 | |
| Median (q1, q3) [range] | 2.0 (0, 4) [0-13] | 5.0 (3, 7) [0-10] | |
| Treatment Lines (n = 120) | |||
| ECOG prior to treatment (n = 120/120)a | .07 | ||
| 0-1 | 54 (81) | 49 (92) | |
| ≥2 | 13 (19) | 4 (8) | |
| Neutrophil count prior to treatment (n = 112)a | .01 | ||
| ≤3500/μL | 21 (42) | 44 (66) | |
| >3500/μL | 29 (58) | 23 (34) | |
| CRP level prior to treatment, mg/L (n = 64)a | .001 | ||
| ≤5 | 11 (35) | 17 (71) | |
| >5 | 29 (65) | 7 (29) | |
| Immune-related adverse events (n = 120)a | .19 | ||
| No | 31 (46) | 18 (34) | |
| Yes | 36 (54) | 35 (66) | |
| Maximum grade of adverse events (n = 120)a | .63 | ||
| 0 | 20 (36) | 13 (27) | |
| I-II | 23 (41) | 23 (48) | |
| III-IV | 13 (23) | 12 (25) | |
Abbreviations: AJCC, American Joint Committee on Cancer; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CIRS, cumulative illness rating score; CRP, C-reactive protein; ECOG, Eastern Cooperative Oncology Group; q, quartile.
SI conversion factors: To convert CRP to nanomoles per liter, multiply by 9.524; to convert neutrophil count to 109/L, multiply by 0.001.
a
A total of 92 patients received 120 lines of treatments. Characteristics of the patients or of the tumor that are unlikely to vary according to treatment line are reported by patient (n = 92). Characteristics that may vary according to treatment line are reported by treatment line (n = 120).